The presence of monoclonal Ig-associated deposition disease (IgDD), such as primary amyloidosis (AL), as a cause of cardiac failure is considered to be a contraindication for cardiac transplantation because the underlying plasma-cell dyscrasia might eventually affect the donor heart. Here we report on a patient in whom the presence of IgDD was retrospectively recognized as the cause of three successively failing hearts including two allografts. Blood progenitor-cell-supported high-dose melphalan therapy fully restored the function of the second transplanted heart, although the serum concentration of the presumably tissue-damaging Ig was only modestly reduced. This case challenges current medical practice of denying patients with IgDD access to cardiac transplants, as the application of high-dose chemotherapy, aimed at reducing the offending Ig-secreting plasma-cell clone, proved successful in restoring normal function and seemingly eliminating IgDD infiltration in the second cardiac graft. that was attributed to IgDD on repeat biopsy. After administration of melphalan (210 mg/m 2 ) with blood progenitor-cell support comprising 3.35 Â 10 6 CD34 þ cells/kg, the patient recovered normal cardiac function (LVEF, 450%) by April 2008, although serum monoclonal protein levels decreased by not more than 50%. A further heart biopsy in September 2008 revealed no evidence of IgDD and stable low levels of serum-M in the 0.7 g/100 ml range. The patient is entirely asymptomatic, can climb three flights of stairs without distress and works full time.
Cardiac IgDD manifests itself as either heart failure and arrythmia. 5 The deposition may be comprised of fibrillar (amyloidogenic) or non-fibrillar (non-amyloidogenic) Ig light-chains, Ig-heavy chains or intact Ig molecules, and the presence of both has been reported in various organs. 6 Regardless of the type of Ig deposition, patients with cardiac manifestations have a short-median survival not exceeding 6 months. 7 High-dose melphalan therapy with autograft support has substantively altered patients' prognoses, especially when the offending Ig-secreting clone was maximally reduced and 'complete response' was achieved, as defined by absence of monoclonal Ig on immunofixation analysis. 8 In cases involving failure of organ function to improve after high-dose therapy, cardiac and other organ transplants have been applied, provided that serological complete response had been obtained and sustained. 9 To our knowledge, there have been only two earlier reports of cardiac transplants preceding high-dose chemotherapy with autograft support. 7, 8 Our patient's clinical course points out several unique aspects: (1) the difficulty of identifying IgDD in affected organs, especially heart, despite repeated biopsies; (2) repeatedly failing cardiac function despite only miniscule morphological evidence of IgDD, pointing to mechanisms other than gross organ infiltration as the cause of organ dysfunction, as suggested by Weichman et al. 10 (3) full cardiac recompensation in a second transplanted heart despite persistence of monoclonal Ig, suggesting other offending mechanisms.
For clinical practice, we recommend that a broadly based team of experts be involved in the clinical management of such desperately ill patients, who still might qualify for lifesaving organ transplants after meticulous selection process instead of being automatically excluded on account of not fulfilling contemporary indications.
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